Celyad SA (CYAD)
| Previous close | 4.2700 |
| Open | 4.2800 |
| Bid | 4.2400 x 1000 |
| Ask | 4.5400 x 1300 |
| Day's range | 4.2800 - 4.3400 |
| 52-week range | 3.7600 - 10.3100 |
| Volume | 5,920 |
| Avg. volume | 25,725 |
| Market cap | 66.937M |
| Beta (5Y monthly) | 1.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4880 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 17.47 |
- Globe Newswire
Celyad Oncology Announces September 2021 Conferences Schedule
MONT-SAINT-GUIBERT, Belgium, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate at the following conferences in September 2021: 2021 Wells Fargo Virtual Healthcare ConferenceDates: Thursday, September 9 – Friday, September 10, 2021Presentation date: Thursday, September
- Globe Newswire
Celyad Oncology Reports First Half 2021 Financial Results and Recent Business Highlights
•Enrollment continues at dose level three in Phase 1 IMMUNICY-1 trial evaluating CYAD-211 in relapsed/refractory multiple myeloma (r/r MM); next clinical update expected by year-end 2021 •Phase 1b KEYNOTE-B79 trial set to evaluate CYAD-101 with KEYTRUDA® in metastatic colorectal cancer (mCRC) patients with microsatellite stable disease on-track to begin in the fourth quarter of 2021 •IND-enabling studies in progress for first-in-class shRNA-based allogeneic, IL-18-armored CAR T candidate CYAD-20
- Globe Newswire
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
MONT-SAINT-GUIBERT, Belgium, July 30, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, announced on July 30, 2021, a capital increase of 300,000 new shares of the Company to Lincoln Park Capital Fund, LLC (“LPC”), a Chicago-based institutional investor. As a result, the Company’s share capital is increased to 54,956,224.33 EUR and
